Get startedLog in
    Picture of Sumitomo Pharma Co logo

    4506 — Sumitomo Pharma Co Cashflow Statement

    0.000.00%
    jp flag iconLast trade - 00:00
    HealthcareHighly SpeculativeLarge CapTurnaround
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual cashflow statement for Sumitomo Pharma Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

    2022
    March 31st
    2023
    March 31st
    2024
    March 31st
    2025
    March 31st
    2026
    March 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:YuhoYuhoYuhoYuhoTanshin
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS    		—
    Status:FinalFinalFinalFinalFinal
    Net Income/Starting Line40,600-96,714-314,92923,635106,865
    Depreciation
    Non-Cash Items49,85087,168118,520-17,691-37,597
    Unusual Items
    Other Non-Cash Items
    Changes in Working Capital-97,559-20,915-82,114-28,178-5,167
    Change in Accounts Receivable
    Change in Inventories
    Change in Accounts Payable
    Change in Other Liabilities
    Other Operating Cash Flow
    Cash from Operating Activities31,23910,802-240,7583,32884,887
    Capital Expenditures-13,494-12,742-15,730-13,030-7,312
    Purchase of Fixed Assets
    Purchase / Acquisition of Intangibles
    Other Investing Cash Flow Items-4,78465,16148,766112,78429,861
    Sale of Fixed Assets
    Sale/Maturity of Investment
    Change in Net Investments
    Purchase of Investments
    Sale of Intangible Assets
    Other Investing Cash Flow
    Cash from Investing Activities-18,27852,41933,03699,75422,549
    Financing Cash Flow Items-870-197,436659566-324
    Other Financing Cash Flow
    Total Cash Dividends Paid
    Net Issuance / Retirement of Debt
    Cash from Financing Activities-21,426-146,81777,851-108,836-91,266
    Foreign Exchange Effects
    Beginning Cash Balance
    Ending Cash Balance
    Net Change in Cash9,286-59,506-114,431-5,93121,194